Gestational trophoblastic disease, for which hydatidiform mole is the most common form, involves abnormal trophoblastic proliferation that can significantly impact a patient’s endocrine system. A prospective observational study conducted at the Srirama Chandra Bhanja Medical College and Hospital in Cuttack, Odisha, India, investigated the relationship between thyroid hormone levels and serum β-human chorionic gonadotropin (β-hCG) concentrations in these patients.
Thyroid Dysfunction in Molar Pregnancy
The research, which analyzed data from January 2022 to December 2023, identified a hospital-based frequency of 5.5 hydatidiform mole cases per 1,000 deliveries. Out of 15,844 total deliveries during the study period, 88 women were confirmed to have hydatidiform moles via histopathological analysis. The cohort was split between 57 cases of complete mole (64.8%) and 31 cases of partial mole (35.2%).
Hormonal Interactions and Clinical Findings
The clinical significance of molar pregnancy lies in the markedly elevated concentrations of serum hCG. Because the molecular structure of hCG is similar to that of thyroid-stimulating hormone (TSH), these high levels can stimulate TSH receptors, potentially leading to thyroid dysfunction.
The study found a statistically significant difference in thyroid hormone profiles between the two types of molar pregnancy. Patients diagnosed with a complete mole exhibited significantly lower TSH levels, measured at 0.82 ± 0.71 µIU/mL, compared to those with a partial mole, who presented with levels of 1.96 ± 0.82 µIU/mL. The researchers utilized Pearson’s correlation coefficient to analyze the relationship between serum β-hCG and various thyroid hormone parameters to better understand the extent of this hormonal cross-reactivity.
Broader Context of hCG and Hyperthyroidism
The link between elevated hCG and thyroid health is observed across various gestational conditions. Research involving patients with gestational trophoblastic neoplasia (GTN) treated with chemotherapy has shown that biochemical hyperthyroidism can occur in a subset of patients. For instance, in a review of 196 patients treated in Sheffield between 2005 and 2010, 7% (14 patients) presented with biochemical hyperthyroidism, while four of those individuals exhibited evidence of clinical hyperthyroidism.
In these cases, a common threshold for such endocrine complications appears to be exceptionally high hCG levels. Data from the Sheffield review indicated that all patients who developed hyperthyroidism presented with hCG levels exceeding 100,000 IU/L, with the majority falling between 100,000 and 500,000 IU/L. Clinically, hyperthyroidism in these contexts is often defined by suppressed TSH levels and elevated free thyroid hormones, highlighting the necessity of monitoring thyroid function in patients presenting with high concentrations of human chorionic gonadotropin.
Distinguishing Pathogenic Mechanisms
While hCG is widely recognized for its role in stimulating the thyroid in molar pregnancies, researchers continue to investigate other factors that influence pregnancy-related symptoms. For example, the GDF15-GFRAL axis is currently considered by many to be a primary pathogenic mechanism for nausea and vomiting of pregnancy. While hCG peaks correlate with the timing of these symptoms—typically between gestational weeks 12 and 14—the pathogenesis of pregnancy-associated conditions remains a complex field involving multiple hormonal and genetic variables. Understanding how these specific factors, such as hCG-induced thyroid stimulation, differ from other systemic stressors is essential for the clinical management of patients with trophoblastic disease.
По теме
